Pro-Dex (NASDAQ:PDEX) Upgraded by Zacks Research to “Strong-Buy” Rating

17 Sep 2026, 12:04 by Kim Johansen · The Markets Daily

Pro-Dex (NASDAQ:PDEX – Get Free Report) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Tuesday, Zacks reports.

Other equities research analysts have also recently issued research reports about the company. Ascendiant Capital Markets boosted their target price on Pro-Dex from $70.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, September 11th. Wall Street Zen raised Pro-Dex from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings upgraded Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, September 4th. One investment analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $74.00.

Check Out Our Latest Stock Analysis on PDEX

Pro-Dex Stock Up 7.4%

Pro-Dex stock opened at $71.85 on Tuesday. Pro-Dex has a 52 week low of $23.47 and a 52 week high of $77.00. The stock has a market cap of $229.92 million, a price-to-earnings ratio of 17.40 and a beta of 0.06. The company’s 50-day moving average price is $62.92 and its two-hundred day moving average price is $58.37. The company has a current ratio of 4.10, a quick ratio of 2.45 and a debt-to-equity ratio of 0.28.

Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its quarterly earnings results on Thursday, September 3rd. The medical instruments supplier reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.20. The company had revenue of $20.40 million during the quarter, compared to analyst estimates of $19.20 million. Pro-Dex had a net margin of 17.62% and a return on equity of 25.13%. On average, analysts expect that Pro-Dex will post 3.09 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Alisha Charlton sold 2,300 shares of the stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total transaction of $140,990.00. Following the completion of the sale, the chief financial officer directly owned 21,870 shares of the company’s stock, valued at $1,340,631. This represents a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kirk Richard Lee Van, Jr. sold 765 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $59.36, for a total transaction of $45,410.40. Following the sale, the chief executive officer directly owned 79,228 shares of the company’s stock, valued at approximately $4,702,974.08. This represents a 0.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 22,300 shares of company stock worth $1,351,657 over the last quarter. Insiders own 45.90% of the company’s stock.

Institutional Investors Weigh In On Pro-Dex

A number of institutional investors and hedge funds have recently modified their holdings of PDEX. Navellier & Associates Inc. bought a new stake in shares of Pro-Dex during the 2nd quarter worth $322,000. Morgan Dempsey Capital Management LLC raised its position in shares of Pro-Dex by 6.2% during the first quarter. Morgan Dempsey Capital Management LLC now owns 5,808 shares of the medical instruments supplier’s stock worth $286,000 after purchasing an additional 339 shares during the period. Corsair Capital Management L.P. acquired a new stake in shares of Pro-Dex during the first quarter worth $532,000. Bank of New York Mellon Corp acquired a new stake in shares of Pro-Dex during the second quarter worth $678,000. Finally, Punch & Associates Investment Management Inc. lifted its holdings in shares of Pro-Dex by 23.4% during the fourth quarter. Punch & Associates Investment Management Inc. now owns 60,000 shares of the medical instruments supplier’s stock valued at $2,309,000 after purchasing an additional 11,392 shares during the last quarter. Institutional investors and hedge funds own 15.28% of the company’s stock.

More Pro-Dex News

Here are the key news stories impacting Pro-Dex this week:

Positive Sentiment: Ascendiant raised its FY2027 EPS forecast to $3.09 from $2.78, while increasing estimates for Q1, Q2, and Q3 2027. The firm also lifted its Q4 2027 forecast to $0.87 from $0.70, signaling expectations for stronger profitability at the medical-instruments supplier.
Positive Sentiment: Ascendiant maintained a Buy rating and a $74 price target. Its longer-term projections call for FY2028 EPS of $3.36, with quarterly estimates ranging from $0.77 to $0.91.
Positive Sentiment: The revised FY2027 outlook is above the previously cited $2.78 consensus estimate, which may reinforce the view that Pro-Dex’s earnings momentum is improving.

Pro-Dex Company Profile

(Get Free Report)

Pro-Dex, Inc is a medical device manufacturer that designs, develops and produces powered surgical instruments and related equipment. The company primarily serves original equipment manufacturers (OEMs), which incorporate Pro-Dex products into surgical systems sold under their own brands.

Its product portfolio includes battery-powered and electric handpieces, controllers, drivers, saws, microdebriders and other precision instruments used in medical and dental procedures. Pro-Dex also provides related components and accessories, including batteries, chargers and instrument controls, as well as engineering, manufacturing and product-development support for its customers.